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We have developed a generic platform to undertake the analysis of protein copy number from 
single cells.  The approach described here is ‘all-optical’ whereby single cells are manipulated into 
separate analysis chambers using an optical trap; single cells are lysed by a shock wave caused by 
laser-induced microcavitation; and the protein released from a single cell is measured by total 
internal reflection microscopy as it is bound to micro-printed antibody spots within the device.  10 
The platform was tested using GFP transfected cells and the relative precision of the measurement 
method was determined to be 88%.  Single cell measurements were also made on a breast cancer 
cell line to measure the relative levels of unlabelled human tumour suppressor protein p53 using a 
chip incorporating an antibody sandwich assay format. These results suggest that this is a viable 
method for measuring relative protein levels in single cells.    15 
Introduction 
There are a number of reasons to analyse protein copy number 
and protein post translational modifications at the level of 
single cells. Firstly, there is the case of rare or precious cells 
where the limited quantities available give the researcher no 20 
choice. A good example of this is the analysis of circulating 
tumour cells where there can be as few as one cell in a clinical 
blood sample1. Secondly is the situation where cell to cell 
variation masks the properties of interest or where the 
variation from cell to cell actually is the property of interest.   25 
Examples of this can be found in the study of genetically 
identical bacterial populations2. Finally, there is the interest in 
sub-cellular properties such as location of cellular components 
and/or co-location of cellular components.  Despite recent 
advances that offer control of single cells3, in terms of 30 
manipulation and sorting and the ability to measure gene 
expression, the need to measure protein copy number remains 
unmet.  Measuring protein copy number in single cells and 
related quantities such as levels of phosphorylation and 
protein-protein interaction is the basis of single cell 35 
proteomics. 
The combination of fluorescent labelling of proteins, 
particularly using genetically engineered constructs, such as 
fluorescent fusion proteins, and modern microscopy has 
proven to be a particularly powerful combination for single 40 
cell analysis. This approach has in recent years started to 
uncover the connectivity of protein networks including some 
fascinating reports of pulsitile behaviour such as in the case of 
the creation of pulses of p53 in response to a DNA-damaging 
stimulus4.  The combination of microscopy and fusion protein 45 
labelling is extremely powerful and will no doubt continue to 
provide important new insights. It does, however, have some 
significant limitations. Firstly, there is always the concern that 
the inclusion of fusion proteins can alter the biology 
observed5, 6. Perhaps more limiting however are the 50 
restrictions caused by the need to use genetically engineerable 
cells. This is particularly problematic for human samples and 
in particular for human clinical samples. Moreover, although 
immortal cell lines are easily engineered and studied, many of 
these cell lines have biology which is greatly altered from the 55 
biology of the human tissue from which it originates. This is 
due to a combination of their origins as cancerous cells and 
their genetic instability over many years of culture in many 
different laboratories around the world under many different 
conditions7. Furthermore, there is no practicable method for 60 
engineering human clinical samples either from healthy 
volunteers or from sick patients such that they can be studied 
using fusion protein labels. Finally, there is the restriction on 
multiplexing signals from multiple labels for multiple 
proteins. The current practical limit for live cells is three or 65 
four different labels, and even then, if stable cell lines are 
required, the practicalities mean that such experiments are 
rarely undertaken. 
In this paper we outline a single cell proteomic technology 
that is relatively scalable in terms of the ability to study 70 
multiple proteins in parallel. More importantly, it requires no 
genetic engineering of the samples and can therefore be 
applied to human tissue and clinical samples. It can also in 
principle be adapted to the study of protein-protein 
interactions and phosophorylation. 75 
The single cell proteomic technology described here includes 
a number of components that are combined within a single 
experimental arrangement to produce a practicable workflow. 
The elements of this process are 1) single cell collection, 
manipulation and reliable loading of cells into the analysis 80 
device; 2) reproducible lysis of the cells and 3) analysis of the 
contents of the lysed cell. Each of these steps has many 
independent solutions and the overall workflow can therefore  
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Fig. 1 (a) Schematic of the device used for single cell experiments.  (b) Schematic of the optical setup. 473cw = cw TIRF laser at λ = 473 nm, 1064p = 
pulsed Nd:YAG laser at λ = 1064 nm, 1070cw = cw Ytterbium fibre laser at λ = 1070 nm, M = mirror, FM = flip mirror, PM = periscope mirrors, λ/2 = half-
wave plate, PBS = polarising beam splitter, L1 & L2 =lenses in beam expander , MTU = Nikon motorised TIRF unit, FC = filter cube.  (c) – (e) 3-step 
workflow employing optical methods to isolate and trap cells, lyse and subsequently analyse protein content in a single cell.  (c) The optical trap is used 5 
to move cells (green circles) from flow to analysis chambers.  Inset: brightfield image of an antibody spot aligned within a chamber.  Scale bar = 100 μm.  
(d) Single cells (green circles) are lysed by the delivery of a single 6 ns pulse at λ = 1064 nm 10 μm above the centre of the cell.  (1) At sufficient 
irradiance the medium breaks down to form a localised plasma; (2) An outwardly propagating shockwave and an expanding cavitation bubble are 
produced; (3) the cell is lysed due to shear stress from the expanding cavitation bubble; and (4) cellular constituents are released into the chamber.  (e)  
Single cell protein levels are measured using an antibody spot.  Chamber volume is 4.6 nL and results in favourable kinetics.  By employing TIRF, only 10 
fluorophores within 200 nm of the surface are imaged, which are assumed to be antibody/antigen bound. 
be constituted in a variety of ways. In this paper we give the 
first example of such a workflow exemplified by three 
particular choices of the elements described above. Crucially, 
these elements allow the study in principle of any protein of 15 
interest, in any cell type of interest, with single cell 
sensitivities and without the need for genetic engineering. We 
name this class of device Microfluidic Antibody Capture 
chips, or MAC chips for short.  We show that the precision 
and fidelity of the combined workflow is sufficient to produce 20 
data that will is revealing of cell to cell variation in protein 
copy number and demonstrate the first measurement of 
‘native’ cell to cell protein copy number variation using the 
tumour suppressor protein p53 as an example. 
Materials and Methods 25 
Cell Culture and Preparation 
BE colon carcinoma cell line was used as previously 
described8 and transfected to express cytoplasmic GFP.  The 
cells were cultured using Dulbecco’s Modified Eagles 
Medium (DMEM; Invitrogen, UK)) supplemented with 10% 30 
(v/v) foetal bovine serum (FBS; Sigma, UK).  Cells that were 
used in experiments were detached from culture flasks using 
trypsin (Invitrogen, UK), which was inactivated by suspension 
in 4% bovine serum albumin (BSA; Sigma, UK) and 10% 
culture medium in phosphate-buffered saline (PBS; 35 
Invitrogen, UK).  A suspension of single cells was created by 
gentle agitation with a pipette before sieving through a nylon 
mesh of 40m pitch (BD Falcon, UK) to remove any cell 
clumps.  MDA-MB468 is a breast cancer cell line. The cells 
   
were cultured in a 1:1 mixture of DMEM and Ham's F12 
nutrient mixture (DMEM/F12 HAM; Invitrogen, UK) media 
supplemented with 10% (v/v) foetal bovine serum (FBS; 
Sigma, UK). Cells were detached from from culture flasks 
using trypsin, which was inactivated by culture medium.  5 
Antibodies 
AntiGFP monoclonal antibody was raised in BALB/c mice 
and donated by Pr. P. Parker (Cancer Research UK, Lincoln’s 
Inn Fields Laboratories).  It was dialysed into phosphate 
buffered saline (Invitrogen, UK), aliquoted and stored at -80 10 
°C before use.  P53 protein is detected using an antibody 
sandwich assay.  The antip53 primary antibody is taken from 
a commercial test kit (p53/Mdm2; Enzo Life Science, UK) 
whose epitope is at the C-terminus of the protein.  The 
secondary antibody is the DO1 monoclonal antibody 15 
recognising amino acids 21-25 at p53’s N-terminus and is 
fluorescently labelled with Alexa-Fluor 488 (sc-126; Santa 
Cruz, USA).  All antibodies have been validated with native 
and non-native Western blots using cell lysate (data not 
shown). 20 
Printing of Antibody Arrays 
Coverslips were surface derivitised with (3-
glycidoxypropyl)trimethoxy silane (GPTS; Sigma, UK).  
Slides were first cleaned by 30 min Sonication in ethanol 
(VWR, UK), then immersed in 10% sodium hydroxide (VWR, 25 
UK) for 1 h.  They were rinsed four times in water and twice 
in ethanol, then immersed in 2.5% GPTS in ethanol for 1 h, 
followed by 10 min sonication to remove unreacted linker.  
Coverslips were forced-air dried and used immediately for 
antibody printing.  All antibodies were printed by an 30 
OmniGrid Micro microarrayer (Digilab, UK) using 946MP2 
pins (ArrayIt, USA) and spotting solution comprised of 
commercial protein print buffer (ArrayIt, USA) supplemented 
with 0.5% PVA (molecular weight 9,000-10,000; Sigma, UK).  
The final concentration of antiGFP and antip53 in spotting 35 
solution were 90 μg/mL and 62.5 μg/mL, respectively.  Spot 
to spot variation was determined by incubating antibody spots 
with purified antigen protein and 50% of print runs show a 7% 
spot to spot variation or lower; those print runs that do not 
achieve this target are rejected. 40 
Microfluidic Device Fabrication 
The single cell analysis device (fig. 1a) was fabricated using 
SU-8-based soft-lithography techniques for PDMS9.  PDMS 
was mixed at a ratio of 10:1 precursor to curing agent and 
poured over the SU-8 mold before being degassed in a 45 
dessicator chamber and set to cure at 60°C for 2+ hours.  The 
Si-wafer surface was passivated by vapour-deposition of 
(tridecafluoro-1,1,2,2-tetrahydrooctyl) trichlorosilane (Sigma-
Aldrich, UK) under vacuum to enable easy lift-off of cured 
PDMS.  The cured PDMS was removed from the mould and 50 
access holes were punched with a needle.  The PDMS was 
bonded to a glass slide (75mm x 50mm x 1mm) channel-side 
away from the glass surface after exposure to an air plasma 
for 1 minute (Harrick Plasma, USA).  The microchannels are 
sealed by a coverslip (thickness #1.5; Corning, UK) upon 55 
which antibody patches are printed in defined locations using 
the Axsys software (Digilab, UK) to drive the microarrayer.  
The antibody microspots are aligned using a home built 
translation stage (inset, fig. 1c).  Plasma treatment would 
obviously destroy antibodies so only the PDMS surface is 60 
plasma treated for irreversible bonding; however, contact 
bonding alone is sufficient to maintain device integrity. 
Experimental system 
Cell manipulation, lysis and subsequent analysis are all 
performed using optical based methods.  The beam paths are 65 
shown schematically in fig. 1b and are all delivered via a 
single 60x NA=1.49 oil-immersion objective.  The design of 
the optical trap is typical of setups described elsewhere10  and 
is formed of a single-beam produced by an Ytterbium fibre 
laser (YLM-5; IPG Photonics, UK) at λ = 1070 nm, with the 70 
objective focal and trapping planes being coincident.  The 
objective lens back aperture is overfilled to ensure stable 
trapping at low powers, typically 50 – 75 mW, measured at 
the back aperture.  A trapped cell is effectively moved within 
the microfluidic by translating a motorised stage.   75 
Optical lysis is performed by the delivery of a single pulse of 
6ns duration at λ = 1064 nm from a Q-sw Nd:YAG laser 
(Surelite SL I-10, Continuum, USA) and has been previously 
shown to preserve cellular protein11, 12.  Briefly, at sufficiently 
high irradiance, non-linear light absorption in the medium 80 
causes it to breakdown resulting in the formation of localised 
plasma, which results in a sequence of shockwave propagation 
and cavitation bubble expansion and subsequent collapse13.  
The primary agent of cell lysis has been shown to be shear 
stresses caused from the expansion of the cavitation bubble.  85 
The process is described in detail elsewhere14.  Pulses, of 
energy defined by a half-wave plate and a polarisation 
sensitive beam splitter, are delivered 10 μm above the  centre 
of the cell to be lysed.  The threshold for plasma formation is 
defined as the pulse energy that results in a 50% probability of 90 
plasma formation.  It was measured in 4% BSA in PBS by 
observing the incidence of bright flashes recorded by the 
camera for 50 pulses at varying energies and determined to be 
9.9 ± 0.4 μJ by fitting to a Gaussian error function15.  For 
single cell lysis pulse energy is set to 14.1 ± 0.3 μJ, which 95 
correspond to 100% probability of plasma formation and 
ensures cells will be lysed by delivery of a single pulse. 
To measure primary antibody bound fluorescent analyte 
(GFP), or bound analyte/secondary antibody complex (p53), 
objective-based total internal reflection microscopy is 100 
employed with an electron-multiplied CCD (IXON DU-897E; 
Andor Technologies, Ireland) for background discrimination 
and single molecule detection capability.  A solid state cw 
laser (MBL-473-200; Laser 2000, UK) at λ = 473 nm is 
coupled into a single-mode optical fibre which is connected to 105 
a motorised TIRF illumination unit (Nikon, Japan).  The 
power at the back aperture is adjusted by neutral density 
filters to 1.5 mW. 
Laser light for optical trapping and lysis were introduced 
through a back-port on the microscope and reflected to the 110 
sample by a single-edge dichroic (LPD01-532R-25; Laser 
2000, UK).  Laser lysis pulses are filtered by a long pass filter 
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Fig. 2 (a) Typical antiGFP antibody spot imaged by TIRF.  Scale bar 25 μm. The antibody spot is located in the lysis chamber, see figure 1c inset brightfield 
image of lysis chamber. (b) Kinetics of protein binding from 3 single BE cells whereby cytosolic GFP is freed upon lysis to bind to an antiGFP antibody 
spot within the same 4.6 nL chamber.  The symbols, squares (■), crosses (X) and circles (●) represent 3 separate measurements of protein from a single 
cell binding to an antibody spot.  The variation between the curves reflects the varying levels of GFP from cell to cell.  (c) Correlation between the 
amount of GFP in cells, as measured by widefield fluorescence, and the amount of GFP bound to each antibody spot, as measured by TIRF, over the 5 
time-course of the experiment.  Widefield fluorescence levels are on the vertical axis and fluorescence from TIRF measurements of protein bound to the 
antibodies on the chip surface is on the horizontal axis. The stars and crosses represent data from two different experiments to give a feel of the 
reproducibility of the methodology. The straight lines are fits to the data and the high degree of correlation shows that the TIRF measurements faithfully 
recover the level of protein as measured by widefield microscopy. 
at launch (LP03-532RS-25; Laser 2000, UK).  For TIRF 10 
illumination a filter set (z488bp; Chroma, USA) was used. 
Experimental procedure 
An inverted microscope (Nikon Ti-E, Nikon, Japan) was used  
as the experimental platform.  Antibody spot position within 
each chamber was recorded using an encoded XY stage 15 
(Nikon, Japan).  The device is degassed and allowed to fill 
with 4% BSA in PBS in a dessicator chamber.  BSA serves to 
block the antibody spots from non-specific binding and to 
prevent cells sticking to the glass while being transported by 
the optical trap.  The device is returned to the microscope and 20 
connected via appropriate tubing to a syringe pump.  BE cells 
were flowed down the main channel of the device at 1 μL min -
1 and upon nearing the entrance to the sorting chamber flow is 
stopped and a cell is moved, by the optical trap, to each 
analysis chamber and placed within the small cubicle (fig. 1c).  25 
MDA-MB468 cells are introduced directly into the sorting 
chamber (fig. 1a) and moved from there.  The cubicle protects 
the cell from displacement upon filling the chambers with 
secondary antibody for experiments with p53.  In the case of 
GFP experiments, cells are imaged prior to lysis using 30 
widefield epi-fluorescence by excitation from a mercury lamp 
through a Nikon standard FITC filter set.  Upon lysis of cells, 
antibody spots are imaged automatically in series by TIRF 
with the focal plane being maintained by a Nikon Perfect 
Focus System (Nikon, Japan). 35 
Single molecule counting 
Single molecule counting.  The number of proteins captured 
per cell to the antibody spot can be estimated from dividing 
the image intensity by the known average intensity of a single 
fluorescence reporter i.e the GFP protein or labelled 40 
secondary antibody.  Images of 10 reporter molecules bound 
to an antibody spot are fit to a two-dimensional symmetrical 
Gaussian function.  The parameters from all fits were 
averaged and used to estimate the number of proteins bound to 
each antibody spot.  The background transient count rate in 45 
one image frame is 100 proteins due to transient non-specific 
binding of the secondary antibodies so that in each frame 
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~100 of the counts are due to this background.  Therefore, in 
our setup the limit of detection for antip53 is 100 proteins  
Results 
Before using MAC chips to study biology it is important to 
demonstrate that they do indeed faithfully measure the protein 5 
level within a single cell and to establish the precision with 
which the MAC chips are able to do this. This is best done by 
measuring the correlation between the levels of protein 
measured by some other method with that determined using 
the MAC chips themselves.  A useful approach is to use 10 
conventional widefield fluorescence microscopy to measure 
the amount of fluorescently tagged protein within a single 
cell, and to correlate this against the level of protein measured 
uising the laser lysis, antibody capture and protein counting 
methods of the workflow described.  To do this we use a cell 15 
line stably transfected with GFP.  GFP expression levels were 
measured for each cell by widefield fluorescence immediately 
prior to lysis and by TIRF subsequent to lysis and capture of 
the protein by the antibody patches.  A time series of images  
 20 
Fig. 3 One, two, three and four MDA-MB468 cells are loaded into 
separate chambers followed by lysis, capture of the protein and analysis.  
The figure shows that the p53 signal increases linearly with cell number 
and that the response is not saturating. 
was acquired every 5 min for 30 min and every 20 min 25 
thereafter.  A typical antiGFP antibody patch bound with GFP  
from a single cell is shown in fig. 2a and the time dependent 
accumulation of protein on the patches shown for 
measurement of 3 separate cells  in fig. 2b.  The binding 
kinetics are approximately described by B(t) = T – U(t) = T(1-30 
e^-kt) where T, B and U are the total, bound and unbound 
amounts of protein; k is the antibody binding constant, here 
2.58 × 10-3 s-1, and t is time.  To minimise photobleaching, 
low excitation power and a short duty cycle of 0.075 - 0.3 % 
are employed; however photobleaching effects are effectively 35 
cancelled out when making relative measurements as we do in 
this paper so long as the experimental conditions are always 
the same.  Simple calculations of the diffusion behaviour in 
these chambers suggest that the 95% of GFP binding should 
be largely complete in approximately 20 minutes, which is 40 
broadly what we find in the data of fig. 2b that shows a 1/e 
time constant of about 6.5 minutes.     
Plots of cellular GFP fluorescence prior to lysis against 
antibody spot fluorescence post lysis is shown in fig. 2c for 
six sequential time points.  The number of GFPs captured per 45 
cell can be estimated by single molecule counting.  The 
number of GFPs bound to each spot at steady state was 
determined.  The minimum number of GFPs bound to a spot 
was 0.41 × 105 GFPs whereas the maximum was 2.7 × 105 
GFPs.  At this point we cannot say definitively whether each 50 
measurment accurately reflects the absolute number of GFP 
molecules from each cell as we do not currently know for 
certain what the capture efficiency of these particular devices 
with this particular antibody is.  
The precision of the MAC chips in measuring the relative 55 
levels of protein can be given a lower limit by making the 
assumption that the widefield fluorescence measurements are 
perfectly precise. In this case the standard deviation between 
the protein levels measured by fluorescence and those from 
the MAC chips is found to be 88%.  This means that the 60 
precision of our method is 88% at worst and could in fact be 
better than this depending on the actual precision of the 
widefield fluorescence measurement methodology. 
In order to make measurements on unlabelled proteins and to 
demonstrate the generality of the methodology we have also 65 
employed a sandwich assay format where a primary antibody 
printed onto the glass surface captures the protein of interest 
while a secondary antibody carrying a fluorescent label, 
present in the chambers at 50 ng/mL, also binds to the 
captured protein in order to make each protein detectable by 70 
TIRF.  To demonstrate this capability we chose to measure the 
amount of p53 in the breast-cancer cell line MDA-MB468.  
Using single molecule counting, it is estimated that 1500 ± 
200 proteins are captured on average from each cell.  In order 
to demonstrate the linearity of the flurorescent signal with 75 
protein copy number, 1-4 cells were deposited in chambers 
and lysed (fig. 3).  As can be seen, the fluorescence increases 
linearly with the number of cells lysed. Those deviations from 
linearity that are visible from the straight line fit to the data 
almost certainly reflect genuine variation in protein copy 80 
number from cell to cell. 
Hu et al., using an ELISA kit, measured p53 protein levels in 
a cell line where p53 expression was regulated by a 
tetracycline promoter16.  Minimum levels were measured at 
0.57 × 105 which increased to 5.9 × 105 upon complete 85 
withdrawal of tetracycline.  Ma et al. have made similar 
measurements17 in 7 different cell lines and report p53 levels 
from 2 - 20 × 104 per cell, 5 lines of which with levels less 
than 5 × 104.  It is highly likely that each cell contains 
significantly more p53 than the 1500 copies captured by our 90 
chips.  The relatively low number that we detect almost 
certainly reflects the high affinity of p53 for DNA and for 
other proteins, the binding of which is likely to obscure the 
recognition epitope for either the primary or secondary 
antibodies. For now therefore, and in the absence of any 95 
further information, the 1500 copies captured are probably 
representative of the fraction of p53 unbound to DNA or other 
proteins. Nevertheless it proves the principle that we can 
reliably determine relative levels of protein in single cells 
without the need to resort to labelling of the proteins. 100 
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Discussion 
One of the more important applications of this technology is 
likely to be the study of protein-protein interactions using a 
primary antibody against one protein and a secondary against 
its binding partner. In these cases it is important that the 5 
epitopes recognised by the antibodies differ from those 
recognised by the proteins.  In the experiments reported here 
we are in effect measuring a popluation of p53 unbound to 
DNA or other proteins since the secondary epitope (aa 21-25) 
overlaps the Mdm2 binding pocket (aa 18-26) and this may 10 
prevent recognition by the secondary18 antibody and therefore 
prevent detection. 
The current design and fabrication methods used in our chips 
leads to a 50% failure rate, largely due to the strict 
requirement upon antibody spot quality for single cell 15 
measurements. The demonstration devices used in this proof 
of principle study have only 7 chambers but this could be 
increased as long as the cells can be loaded in an effective and 
efficient way.  The optical trap may not be ideal for trapping 
large numbers of cells.  However, for studies of rare cells such 20 
as circulating tumour cells (CTCs), where there are often only 
1-10 CTCs per patient sample, the use of optical trapping can 
be a particularly good solution. 
Conclusions 
We have demonstrated the ability count protein copy number 25 
from single cells in a manner which could be applied in 
principle to any set of proteins and for any cell type without 
the need for genetic engineering. The precision of the 
measurements is shown to be ~88%, easily sufficient for 
studying the variation in protein copy number from cell to 30 
cell. 
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